Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chu Hyun Kim has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of deep learning reconstruction in low dose computed tomography on the evaluation of interstitial lung disease

    by Chu Hyun Kim, Myung Jin Chung, Yoon Ki Cha, Seok Oh, Kwang Gi Kim, Hongseok Yoo

    To evaluate the effect of the deep learning model reconstruction (DLM) method in terms of image quality and diagnostic agreement in low-dose computed tomography (LDCT) for interstitial lung disease (ILD), 193 patients who underwent LDCT for suspected ILD were retrospectively reviewed. Datasets were reconstructed using filtered back projection (FBP), adaptive statistical iterative reconstruction Veo (ASiR-V), and DLM. For image quality analysis, the signal, noise, signal-to-noise ratio (SNR), blind/referenceless image spatial quality evaluator (BRISQUE), and visual scoring were evaluated. Also, CT patterns of usual interstitial pneumonia (UIP) were classified according to the 2022 idiopathic pulmonary fibrosis (IPF) diagnostic criteria. The differences between CT images subjected to FBP, ASiR-V 30%, and DLM were evaluated. The image noise and BRISQUE scores of DLM images was lower and SNR was higher than that of the ASiR-V and FBP images (ASiR-V vs. DLM, p < 0.001 and FBP vs. DLR-M, p < 0.001, respectively). The agreement of the diagnostic categorization of IPF between the three reconstruction methods was almost perfect (κ = 0.992, CI 0.990–0.994). Image quality was improved with DLM compared to ASiR-V and FBP.


  • Open Access

    CT findings of basaloid squamous cell carcinoma of the lung in 12 patients

    by Chu Hyun Kim, Yoon Ki Cha, Joungho Han, Jun Ho Kim, Tae Jung Kim, Myung Jin Chung, Jung Hee Lee, Hyun Jung Yoon

    Basaloid squamous cell carcinoma (SCC) is very rare subtype of SCC of the lung and it is important to distinguish basaloid to other subtypes of SCCs, since the prognosis of basaloid subtype is considered poorer than that of other non-basaloid subtypes of SCCs. Aim of this study was to assess computed tomography (CT) findings of basaloid SCC of the lung in 12 patients. From January 2016 to April 2021, 12 patients with surgically proven basaloid SCC of the lung were identified. CT findings were analyzed, and the imaging features were compared with histopathologic reports. Clinical and demographic features were also analyzed. Axial location of the tumor was central in 5 patients, while 7 was in peripheral. Of the 7 patients whose tumors were located in the peripheral, margin of the tumor were smooth (n = 2), lobulated (n = 2), or spiculated (n = 3). After contrast injection, net enhancement value ranged from 15.8 to 71.8 HU (median, 36.4 HU). Endobronchial growth were seen in 5 patients and these patients accompanied obstructive pneumonia or atelectasis. Internal profuse necrosis, cavitation, or calcifications were not seen. On CT, basaloid squamous cell presents as solitary nodule or mass with moderate enhancement. Tumor was located either peripheral or central compartment of the lung and cavitation was absent.


  • Open Access

    Magnetic resonance imaging for lung cancer: a state-of-the-art review

    by So Hyeon Bak, Chohee Kim, Chu Hyun Kim, Yoshiharu Ohno, Ho Yun Lee

    Lung cancer is the leading cause of cancer-related deaths worldwide, and imaging techniques such as chest radiography, computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) play an important role in its diagnosis, staging, treatment planning, post-operative surveillance, and treatment response evaluation. Pulmonary MRI can non-invasively visualize structural and functional abnormalities in the lungs without using ionizing radiation, although it has been suggested that it has less clinical utility than chest radiography, CT, and PET/CT for thoracic diseases, especially lung diseases. With recent advances related to MRI pulse sequences, pulmonary MRI has become practicable in an expanding number of clinical situations. This review article focuses on recent advances in MRI and discusses its clinical applications in the detection, diagnosis, staging, pre-operative evaluation, post-operative surveillance, and treatment response evaluation of lung cancer.


  • Open Access

    Infiltrative invasion of the diaphragm: an uncommon manifestation of recurrent hepatocellular carcinoma

    by Chu Hyun Kim, Kyoung Doo Song, Jung Han Woo

    Purpose: To report on infiltrative invasion of the diaphragm, an uncommon manifestation ofrecurrent hepatocellular carcinoma (HCC), and evaluate its clinical significance.Methods: Using the term “diaphragm” or “diaphragmatic” and “invasion” or “involvement,” we searched for patients in the database of radiologic reports of liver computed tomography or magnetic resonance imaging performed between 2012 and 2016 at our institution. Nine patients with infiltrative invasion of the diaphragm due to recurrent HCC were included. Their clinical and imaging findings were evaluated.Results: The median age of patients at the time of diagnosis was 68 years (range, 40 to 73). There were eight men and one woman. Imaging findings of infiltrative invasion of the diaphragm revealed diffuse thickening with enhancementinvolving a part ofthe diaphragm. The median interval between initial manifestation on imaging and radiologic diagnosis of infiltrative invasion ofthe diaphragm was 6.8 months (range, 3.4 to 18.6). In two of three patients who underwent surgicalresection, tumors of the diaphragm were controlled without recurrence. In six patients except for one patient who was not followed up, tumors recurred at the resection site or diaphragm tumors showed a partial response or disease progression.Conclusion: Infiltrative invasion of the diaphragm by recurrent HCC manifested with diffuse thickening and diaphragm enhancement on radiologic imaging. A good prognosis can be expected only in patients who are diagnosed early and undergo surgical resection.


  • Open Access

    Computed Tomography Radiomics for Residual Positron Emission Tomography-Computed Tomography Uptake in Lymph Nodes after Treatment

    by Chu Hyun Kim, Hyunjin Park, Ho Yun Lee, Joong Hyun Ahn, Seung Hak Lee, Insuk Sohn, Joon Young Choi, Hong Kwan Kim

    Although a substantial decrease in 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) uptake on positron emission tomography-computed tomography (PET-CT) indicates a promising metabolic response to treatment, predicting the pathologic status of lymph nodes (LN) remains challenging. We investigated the potential of a CT radiomics approach to predict the pathologic complete response of LNs showing residual uptake after neoadjuvant concurrent chemoradiotherapy (NeoCCRT) in patients with non-small cell lung cancer (NSCLC). Two hundred and thirty-seven patients who underwent NeoCCRT for stage IIIa NSCLC were included. Two hundred fifty-two CT radiomics features were extracted from LNs showing remaining positive FDG uptake upon restaging PET-CT. A multivariable logistic regression analysis of radiomics features and clinicopathologic characteristics was used to develop a prediction model. Of the 237 patients, 135 patients (185 nodes) met our inclusion criteria. Eighty-seven LNs were proven to be malignant (47.0%, 87/185). Upon multivariable analysis, metastatic LNs were significantly prevalent in females and patients with adenocarcinoma (odds ratio (OR) = 2.02, 95% confidence interval (CI) = 0.88–4.62 and OR = 0.39, 95% CI = 0.19–0.77 each). Metastatic LNs also had a larger maximal 3D diameter and higher cluster tendency (OR = 9.92, 95% CI = 3.15–31.17 and OR = 2.36, 95% CI = 1.22–4.55 each). The predictive model for metastasis showed a discrimination performance with an area under the receiver operating characteristic curve of 0.728 (95% CI = 0.654–0.801, p value < 0.001). The radiomics approach allows for the noninvasive detection of metastases in LNs with residual FDG uptake after the treatment of NSCLC patients.


  • Yield of concurrent systemic biopsy during MRI-targeted biopsy according to Prostate Imaging Reporting and Data System version 2 in patients with suspected prostate cancer

    by Chu Hyun Kim, Chan Kyo Kim, Jung Jae Park, Sung Yoon Park, Young Cheol Yoon

    Objectives To investigate the yield of concurrent systemic biopsy (SB) during MRI-targeted biopsy (MRTB) as Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) interpretations in patients with suspected prostate cancer (PCa). Methods A total of 285 patients with suspected PCa underwent prebiopsy 3-T MRI, followed by MRI-transrectal ultrasound fusion targeted biopsy and concurrent standard SB for lesions with PI-RADS v2 scores 3–5. Detection rates and positive core rates of PCa and clinically significant cancer (CSC) were evaluated. Results In concurrent MRTB and SB, PCa and CSC detection rates were 18.9% and 9.4% for PI-RADS score 3, 45.9% and 32.4% for PI-RADS score 4, and 82.1% and 72.6% for PI-RADS score 5, respectively. Overall detection rate of CSCs (40.0%) for concurrent MRTB and SB was significantly higher than that of MRTB (34.4%, p = 0.004) or SB alone (27.7%, p < 0.001): an increase of 5.6% (16 patients) compared with MRTB alone. For patients with PI-RADS score 4 or 5, the CSC detection rate of concurrent MRTB and SB was 47.0%, an increase of 6.1% when compared with MRTB (40.9%) only (p < 0.001). Of the 110 patients with both MRTB- and SB-positive findings, 22 (20.0%) had the highest Gleason score in SB compared with that in MRTB. In 9.5% (27/285) patients including 12 patients with CSCs, only SB was positive, with negative MRTB. Conclusion Concurrent SB with MRTB based on PI-RADS v2 can yield a higher CSC detection rate compared with MRTB alone in patients with suspected PCa. Key Points • Concurrent SB with MRTB yields an increase of 5.6% CSC detection compared with MRTB alone. • Of both MRTB- and SB-positive findings, 20.0% patients have upgraded Gleason score in SB. • In 18.4% patients, only SB was positive, with negative MRTB. Adding MRTB to SB is helpful for adequate risk stratification, reducing diagnostic uncertainty of PCa.


  • Open Access

    Botryoid Wilms Tumor in a Neonate Presenting with Fetal Hydronephrosis: A Case Report

    by Chu Hyun Kim, So-Young Yoo, Tae Yeon Jeon, Ji Hye Kim, Jung-Sun Kim, Minki Baek

    Botryoid Wilms tumor, a very rare variant of Wilms tumor, arises from the pelvocalyceal system, and its occurrence in the fetal or neonatal period has never been reported in the literature. Herein, we report an exceedingly rare and challenging case of botryoid Wilms tumor in a neonate who initially presented with fetal hydronephrosis. Postnatal ultrasonography revealed multiple lobulating hypoechoic masses with varying degrees of intralesional vascularity within the dilated pelvocalyceal system. To our knowedge, this is a case report of botryoid Wilms tumor of the youngest child in English literature.

  • Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).

    by Youjin Kim, Chu Hyun Kim, Hong Sook Kim, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Ho Yun Lee, Keunchil Park

    9075Background: Hyperprogressive disease (HPD) emerges as a new subset of patients treated with immune-oncology (IO) agent. The definition of HPD is not yet clearly established, and it is unclear which patient is rapidly progressing after IO treatment. We investigated clinical features and potential genomic markers associated with HPD after IO therapy. Methods: We performed a retrospective clinical and radiological analysis of advanced NSCLC patients treated with single IO at Samsung Medical Center(July 2014 to December 2017). CT scans were quantitatively analyzed in terms of tumor volume and tumor growth rate (TGR) by comparing prior vs upon IO. We extracted tumor volume for each metastatic organ, classifying into HPD and non-HPD by volume-based growth kinetics. We also performed deep targeted sequencing of 375 of genes. Results: Of 220 evaluable patients37 patients (17%) were classified as HPD. 26 (70%) were male, 24 (65%) smoker, 25(68%) ≧ 65 years, 10 (27%) ECOG PS ≧ 2, 31(84%) adenocarcinoma. Compare...